Peptide-Drug Conjugates for Cancer: Smaller, Deeper-Penetrating Alternatives to Antibody-Drug Conjugates | Research

The takeaway

Peptide-drug conjugates (PDCs) use small tumor-targeting peptides to deliver cancer drugs deep into tumors with advantages over larger antibody-drug conjugates, but only one PDC (Lutathera) has reached FDA approval so far.

1/100th the size of ADCs
PDCs are 1-3 kDa versus antibody-drug conjugates at ~150 kDa, enabling deeper tumor penetration and faster tissue distribution

What the researchers found

PDCs are small (~1-3 kDa) targeted therapeutics that use homing peptides to deliver cytotoxic drugs to tumors, offering superior tissue penetration and faster clearance compared to antibody-drug conjugates (ADCs, ~150 kDa). Currently, only one PDC is FDA-approved: lutetium (177Lu)-DOTATATE (Lutathera) for neuroendocrine tumors. Other PDCs in development include paclitaxel-Angiopep-2 (ANG1005) for brain tumors and LyP-1-doxorubicin conjugates for triple-negative breast cancer. Key challenges remain: premature drug release, metabolic clearance, variable receptor expression across tumors, and manufacturing scale-up. Melflufen, another PDC, faced clinical setbacks.

Why it matters

Antibody-drug conjugates (ADCs) are already a multi-billion-dollar cancer drug class, but their large size limits how deeply they penetrate tumors. PDCs are essentially the smaller, nimbler cousin — they can reach parts of tumors that antibodies can't and are cheaper to manufacture. With only one FDA-approved PDC so far, the field is still early but has enormous potential, especially with AI-assisted design and theranostic (imaging + therapy) approaches emerging.

The numbers in context

PDCs: ~1-3 kDa · ADCs: ~150 kDa · 1 FDA-approved PDC (Lutathera) · Mechanisms: receptor binding, endocytosis, stimuli-responsive release · Self-assembly capability

How the study worked

Comprehensive narrative review covering PDC design principles (targeting peptides, linker chemistry, drug payloads), mechanisms of tumor delivery and drug release, specific clinical examples, comparison with ADCs, current challenges, and future directions including AI-assisted design and theranostic applications.

What this study cannot tell us

This is a review article, not an experimental study. The field faces significant practical challenges: only one PDC has achieved FDA approval while others (like melflufen) have failed or stalled. The advantages of PDCs over ADCs (better penetration, cheaper manufacturing) must be weighed against disadvantages (faster clearance means shorter drug exposure, potentially requiring more frequent dosing).

How to read the evidence

This is a comprehensive narrative review of the PDC field, covering preclinical and clinical data. Only one PDC (Lutathera) has demonstrated clinical success through FDA approval. The field's overall clinical evidence is limited by the early stage of most PDC programs.

When this study was published

Published in 2026, this is a very current review capturing the latest advances in PDC design, including emerging AI-assisted approaches and theranostic applications.

The bigger picture

ADCs like trastuzumab emtansine (Kadcyla) and enfortumab vedotin (Padcev) have become blockbuster cancer drugs, validating the concept of targeted drug delivery. PDCs represent the next evolution — achieving similar targeting with dramatically smaller, cheaper molecules. The review arrives at an inflection point: AI-assisted peptide design could dramatically accelerate PDC discovery, and theranostic PDCs (combining imaging and therapy in one molecule, like Lutathera) represent a paradigm shift in personalized cancer treatment. However, the field must overcome the disconnect between promising preclinical data and limited clinical success.

Questions still open

Can AI-designed PDCs overcome the stability and premature release challenges that have limited clinical success?
Will PDCs eventually compete with or complement ADCs in oncology, or will they serve different tumor types?
Could theranostic PDCs become standard practice — imaging first to confirm targeting, then treating the same patient?

Common questions

What's the difference between a PDC and an antibody-drug conjugate (ADC)?

Both attach cancer drugs to a targeting molecule that finds tumors. ADCs use large antibodies (~150 kDa) as the targeting vehicle, while PDCs use small peptides (~1-3 kDa). The smaller size of PDCs lets them penetrate deeper into solid tumors, clear from the body faster, and cost less to manufacture. The tradeoff is that PDCs may circulate for less time in the bloodstream.

Why is only one PDC FDA-approved if the concept is so promising?

PDCs face real-world challenges: drugs can detach from the peptide too early (causing side effects), tumors may not consistently express the targeted receptor, and manufacturing at scale is tricky. Lutathera succeeded partly because it uses a well-characterized receptor (somatostatin) on neuroendocrine tumors. Other PDCs like melflufen faced setbacks in clinical trials, highlighting the gap between lab promise and clinical success.

Read the original research

Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles.

Drug design, development and therapy, 20, 562135

View on PubMed ↗Publisher’s paper ↗

Citation

Parang, Keykavous; Do, Thuy; Dinh, Clare; Davani-Davari, Dorna; Foroughi, Max; Khong, Troy; Moazen, Mahsa; Nasrolahi Shirazi, Amir. (2026). Tumor Targeting with Peptide-Drug Conjugates: Showcasing Key Progress and Hurdles.. Drug design, development and therapy, 20, 562135. https://doi.org/10.2147/DDDT.S562135